From central IRBs, certified raters, to local transport: Changes large and small are needed to ramp up drug testing in Alzheimer’s.
Award recognizes his contributions to basic and clinical research.
With three trials and initiatives to boost recruitment, GAP-Net is gaining some traction in the field.
Experts said Phase 3 data did not prove the device could slow AD.
Among 20 focus areas, 47 research recommendations cover the gamut from basic science to health disparities.
At Keystone, the work of several groups painted TREM2 as a dedicated supporter of microglial function across neurodegenerative disease models, including those for ALS.
Screen identifies antibody that induces mouse bone marrow cells to differentiate and travel to the brain, where they clear plaques.
A majority of amyloid PET scans led physicians to change how they managed a patient’s disease. The effect on later outcomes is yet to be come.
Transcranial, alternating electrical current restored neuronal synchrony in older people, rejuvenating working memory. For an hour or two.
Subgroup analysis addresses APOE4 randomization imbalance, claims treatment with this anti-Aβ protofibril antibody slowed cognitive decline.
Hunting for rare mutations that cause dementia, researchers have spotted, but not yet snagged, some tantalizing candidates.
The May 26 Nature Neuroscience online debuts 25 new candidate genes for amyotrophic lateral sclerosis...
After years of grunt work on next-gen sequencing and expression analysis, geneticists are finally reaping results. The new genes underscore the role of known pathways and cell types in disease.
Presented at AD/PD, the discovery by scientists in Uppsala is the first APP deletion found to cause Alzheimer’s disease. The same group found the Swedish and Arctic APP mutations.
Long-term treatment with the anti-sense oligonucleotide led to motor benefits in an extension trial of children 2 to 15 years old.